Achieve Life Sciences, Inc.ACHV

Achieve Life Sciences is a clinical-stage specialty pharma outfit gambling that cytisinicline-a plant-derived alkaloid with a six-decade safety history-can elbow its way into the crowded nicotine-dependence market, currently dominated by nicotine-replacement therapies and prescription drugs with patchy adherence. The company’s pipeline rests on three late-stage trials: ORCA-1 (Phase 2 dose-ranging), ORCA-2 (Phase 3 double-blind, placebo-controlled), and ORCA-3 (Phase 3 open-label safety and efficacy). The product pages on the company’s site still read like placeholders rather than proof, with ORCA-2’s data “expected in Q2 2022” and ORCA-3 “enrolling now,” a timeline that has slipped past its sell-by date. (source: Phase 3 ORCA-2 Trial - Achieve Life Sciences, https://achievelifesciences.com/products/phase-3-orca-2-trial/; Phase 3 ORCA-3 Trial - Achieve Life Sciences, https://achievelifesciences.com/products/phase-3-orca-3-trial/)

The company’s operating model is straightforward: outsource the heavy lifting. In the final quarter of 2025, Achieve inked three development agreements with Adare Pharma Solutions to perform analytical and drug-product development for cytisinicline, and hired a consultant, Kristen Slaoui, to chase “strategic business development and transaction advisory support.” The board, meantime, is being refreshed with industry veterans: the June DEF-14A proposes adding Michael Sellig, whose global pharma-services background is undeniable, while shareholders watch diluted shares climb past 53.4 million in the quarter ending 31 March 2026. The optics are textbook pharma theatre: a management desks that looks like a who’s-who of nicotine-industry infrastructure, paired with a balance sheet that looks like it ran a tab at the cash bar. (source: ACHV DEF 14A, https://www.sec.gov/Archives/edgar/data/949858/000094985826000006/achv-20260604.htm)

Filings paint a starkly different picture from the clinical narrative. By 31 March 2026, Achieve reported a net loss attributable to parent of $10.2 million, negative operating cash flow of $6.9 million, and $28.1 million in cash and cash equivalents against liabilities of $22.4 million and equity of just $10.7 million. Diluted earnings per share came in at minus $0.19 on 53.4 million diluted shares outstanding. Capitalised development costs sit on the balance sheet, but the company’s capex for the year ended 31 December 2025 was a rounding error at $3,000, while research and development expense clocked in at $5.3 million for the quarter ending 30 September 2025. The company’s latest 13G filing, dated 8 July 2026, shows a single reporting person moving toward a 5% stake; no buybacks, no dividends, just a micro-cap stock trading on hope and a 2022-era website banner. (source: ACHV 10-Q, https://www.sec.gov/Archives/edgar/data/949858/000119312526218177/achv-20260331.htm; ACHV SCHEDULE 13G, https://www.sec.gov/Archives/edgar/data/949858/000121390026076390/xslSCHEDULE_13G_X02/primary_doc.xml)

Charts for this name trade on thin liquidity and erratic volume; the company’s thin float and micro-cap designation mean the tape is best read as a sentiment signal rather than a technical reference. Achieve’s stock is listed on the Nasdaq Capital Market under the ticker ACHV; the SEC filings are the only authoritative route to the company’s numbers, and the company’s own investor-relations site links back to those filings. Clinical catalysts-positive ORCA-2 or ORCA-3 data-would change the file immediately, but until then the market is pricing a binary event with a very long expiry date. (source: SEC EDGAR CIK 949858 index, https://www.sec.gov/edgar/browse/?CIK=949858)

The company’s operating reality is also a governance reality: the board’s push to add Sellig is framed as “extensive global experience in the life sciences and pharmaceutical services industries,” yet the balance sheet shows the company has outsourced its most critical path item-drug-product development-to Adare Pharma, a third party, while the cash haemorrhage continues. The 8-K filed on 6 July 2026 confirms no material new financing or asset sale, leaving the company reliant on the existing $28.1 million cash pile and the hope that Phase 3 data will finally justify the narrative. The filing also confirms the board’s proposal to add Sellig is non-controversial, which in governance terms means “no one bothered to object,” not “this is a slam dunk.” (source: ACHV 8-K, https://www.sec.gov/Archives/edgar/data/949858/000119312526296174/achv-20260702.htm)